04:30 AM EST, 02/14/2025 (MT Newswires) -- Oculis Holding ( OCS ) said Thursday it priced an underwritten offering of 5 million ordinary shares at $20 apiece, targeting gross proceeds of $100 million.

The company said the "oversubscribed" offering will likely close on or about Feb. 18. The new shares will bring the total number of registered shares to more than 53.9 million before closing.

Oculis intends to use the net proceeds to, among other things, advance and accelerate its clinical development pipeline, particularly its neuroprotective clinical candidate Privosegtor, or OCS-05.